Clinical trial
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in…
NCT00171340 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171340 |
|---|---|
| Title | Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer. |
| Official title | An Open-Label, Randomized, MultiCenter Study to Evaluate the Use of Zolendronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Positive and/or Progesterone Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bone Loss, Breast Cancer |
| Intervention type | Drug |
| Interventions | Zoledronic acid, Letrozole |
| Enrollment | 1,065 |
| Start date | May 1, 2003 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Sep 15, 2005 |
| Last update posted | Apr 16, 2012 |
| Countries | Argentina, Australia, Belgium, Brazil, Chile, China, Colombia, Czechia, Egypt, Finland, France, Germany and 16 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: